We have collected information about Sirna Sojourn From Discovery To Delivery Challenges And Clinics for you. Follow the links to find out details on Sirna Sojourn From Discovery To Delivery Challenges And Clinics.
https://www.researchgate.net/publication/238343945_SiRNA_Sojourn_from_discovery_to_delivery_challenges_and_clinics
SiRNA: Sojourn from discovery to delivery challenges and clinics Article in Systematic Reviews in Pharmacy 1(1) · January 2010 with 26 Reads How we measure 'reads'
https://www.sciencedirect.com/science/article/pii/S0304383516302063
Current siRNA delivery techniques still face obstacles for in vivo gene silencing (), which make it difficult to translate this revolutionary discovery to oncologic clinics.Here we discuss the key concerns raised from recent clinical trials and preclinical studies and explore avenues to develop siRNA cancer therapy to a viable option for oncology care.Author: Tao Wang, Tao Wang, Sarah Shigdar, Hadi Al Shamaileh, Michael P. Gantier, Michael P. Gantier, Wang Y...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3993214/
This study describes a proof-of-concept study on the use of small interfering RNA (siRNA)-immunoliposomes as a therapeutic agent against H5N1 influenza virus infection. siRNA specific for influenza virus nucleoprotein (NP) mRNA was employed as the key antiviral agent to inhibit viral replication in this study.Author: Kannika Khantasup, Kannika Khantasup, Phikulthong Kopermsub, Kridsada Chaichoun, Tararaj Dharakul, T...
https://www.researchgate.net/publication/23960153_Whitehead_KA_Langer_R_Anderson_DG_Knocking_down_barriers_advances_in_siRNA_delivery_Nat_Rev_8_129-138
Whitehead, K.A., Langer, R. & Anderson, D.G. Knocking down barriers: advances in siRNA delivery. ... SiRNA: Sojourn from discovery to delivery challenges and clinics ... focus on delivery ...
http://pharmabiz.com/NewsDetails.aspx?aid=58564&sid=21
Sep 30, 2010 · siRNA delivery: Opportunities & challenges: Gitanjali Kher & Ambikanandan Misra Thursday, September 30, 2010, 08:00 Hrs [IST] In the one decade that have passed since the discovery of RNA interference (RNAi), efforts and huge money have been invested in research to find out the therapeutic application of gene silencing in humans and the number of publications related to RNAi …
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2977003/
Jun 11, 2010 · The site of action of siRNA therapeutics is the cytosol. The barriers to siRNA delivery are multiple and depend on the targeted organs and the administration routes. In general, locoregional delivery of siRNA has fewer barriers compared to systemic delivery.Author: Jie Wang, Ze Lu, M. Guillaume Wientjes, Jessie L.-S. Au
https://link.springer.com/article/10.1007/BF03261897
Dec 13, 2012 · This review describes the progress that has been made to relieve neuropathic pain using siRNA as a tool for treatment. Further, the review discusses the limitations of using naked siRNA as a therapeutic and a scope for the use of suitable packaging or delivery systems.Author: Indu Pal Kaur, Gaurav Sharma
http://www.eurekaselect.com/144854/article
Conclusion: Delivery of siRNA to the target site is the biggest challenge for its application in the clinic. The findings of this review confirmed by encapsulation siRNA in the nanoparticles can overcome these challenges. The rapid progress in nanotechnology has enabled the development of effective nanoparticles as the carrier for siRNA delivery.Author: Neda Shajari, Behzad Mansoori, Sadaf Davudian, Ali Mohammadi, Behzad Baradaran
https://www.sciencedirect.com/science/article/pii/S1818087614000646
Delivery systems for siRNA drug development in cancer therapy. Author links open overlay ... A broad diversity of materials is under exploration to address the challenges of in vivo delivery, including polymers, lipids, peptides, antibodies, aptamers, and small molecules. Successful systems have been developed by rational design or discovered ...Author: Cong-fei Xu, Jun Wang
https://www.thermofisher.com/us/en/home/references/ambion-tech-support/rnai-sirna/tech-notes/getting-started-with-rnai-in-vivo.html
Co-delivery of siRNA with reporter vectors by hydrodynamic tail vein injection provides a starting point for researchers interested in performing RNAi experiments in the liver. There is a need to develop alternative techniques to enable specific delivery to other organs using normal low-pressure injection conditions.
Searching for Sirna Sojourn From Discovery To Delivery Challenges And Clinics?
You can just click the links above. The data is collected for you.
